Monday - November 17, 2025
Pluristyx Collaborates with Breakthrough T1D to Make "Immune-Cloaked" and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies
November 17, 2025
NEW YORK, Nov. 17 -- Breakthrough T1D (formerly JDRF) a non-profit dedicated to funding type 1 diabetes research, posted the following news release:

* * *

Pluristyx Collaborates with Breakthrough T1D to Make "Immune-Cloaked" and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

*

The up to $1.4M collaboration will enable manufacturing "universal" islets containing a drug-inducible safety feature design . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products